Read by QxMD icon Read

p300 ketamine

Ivan Koychev, John Francis William Deakin, Wael El-Deredy, Corinna Haenschel
BACKGROUND: Working memory (WM) deficits are a core feature of schizophrenia. Electrophysiological studies suggest that impaired early visual processing may contribute to impaired WM in the visual domain. Abnormal N-methyl-D-aspartate (NMDA) receptor function has been implicated both in WM and in early visual processing deficits in schizophrenia. We investigated whether ketamine, a noncompetitive NMDA antagonist, would replicate in healthy volunteers the WM performance and early visual processing abnormalities we and others have reported in patients with schizophrenia...
April 2017: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
Daniel H Mathalon, Kyung-Heup Ahn, Edward B Perry, Hyun-Sang Cho, Brian J Roach, Rebecca K Blais, Savita Bhakta, Mohini Ranganathan, Judith M Ford, Deepak Cyril D'Souza
BACKGROUND: N-methyl-d-aspartate (NMDA) receptor hypofunction has been implicated in the pathophysiology of schizophrenia and its associated neurocognitive impairments. The high rate of cigarette smoking in schizophrenia raises questions about how nicotine modulates putative NMDA receptor hypofunction in the illness. Accordingly, we examined the modulatory effects of brain nicotinic acetylcholine receptor (nAChR) stimulation on NMDA receptor hypofunction by examining the interactive effects of nicotine, a nAChR agonist, and ketamine, a non-competitive NMDA receptor antagonist, on behavioral and neurophysiological measures in healthy human volunteers...
2014: Frontiers in Psychiatry
Olivia M Dean, Ashley I Bush, Michael Berk
No abstract text is available yet for this article.
June 1, 2012: Biological Psychiatry
Handan Gunduz-Bruce, Robert M G Reinhart, Brian J Roach, Ralitza Gueorguieva, Stephen Oliver, Deepak C D'Souza, Judith M Ford, John H Krystal, Daniel H Mathalon
BACKGROUND: Auditory mismatch negativity (MMN) and P300 event-related potentials (ERPs) are reduced in schizophrenia patients and healthy volunteers administered the N-methyl-D-aspartate glutamate receptor antagonist, ketamine. In rodents, N-acetylcysteine (NAC), a stimulator of the cystine-glutamate exchanger, attenuates the cognitive and behavioral effects of N-methyl-D-aspartate receptor antagonists. On the basis of these findings, we tested whether NAC would reduce ketamine effects on behavior, MMN, and P300 in healthy humans...
June 1, 2012: Biological Psychiatry
Verner J Knott, Anne M Millar, Judy F McIntosh, Dhrasti K Shah, Derek J Fisher, Crystal M Blais, Vadim Ilivitsky, Ed Horn
Given the cognitive-promoting properties of the nicotinic acetylcholinergic receptor (nAChR) agonist, nicotine, the increased prevalence of smoke-inhaled nicotine in schizophrenia has been interpreted as an attempt to self-correct cognitive deficits, which have been particularly pronounced in the attentional domain. As glutamatergic abnormalities have been implicated in these attentional deficiencies, this study attempted to shed light on the separate and interactive roles of the N-methyl-d-aspartate receptor (NMDAR) and nAChR systems in the modulation of attention by investigating, in healthy volunteers, the separate and combined effects of nicotine and the NMDAR antagonist ketamine on neural and behavioural responses in a sustained attention task...
September 2011: Biological Psychology
Francesco Musso, Jürgen Brinkmeyer, Daniel Ecker, Markus K London, Giesela Thieme, Tracy Warbrick, Hans-Jörg Wittsack, Andreas Saleh, Wolfgang Greb, Peter de Boer, Georg Winterer
BACKGROUND: Behavioral and electrophysiological human ketamine models of schizophrenia are used for testing compounds that target the glutamatergic system. However, corresponding functional neuroimaging models are difficult to reconcile with functional imaging and electrophysiological findings in schizophrenia. Resolving the discrepancies between different observational levels is critical to understand the complex pharmacological ketamine action and its usefulness for modeling schizophrenia pathophysiology...
September 15, 2011: NeuroImage
Bob Oranje, Christine C Gispen-de Wied, Herman G M Westenberg, Chantal Kemner, Marinus N Verbaten, René S Kahn
Antagonists of the N-methyl-D-aspartate (NMDA) receptors such as ketamine, induce abnormalities in healthy subjects similar to those found in schizophrenia. However, recent evidence, suggests that most of the currently known NMDA antagonists have a broader receptor profile than originally thought. Besides exerting an antagonistic effect on NMDA receptors, they have agonistic effects on dopamine D2 receptors. Can haloperidol (D2 antagonist) counteract the disruptive effects of ketamine on psychophysiological parameters of human attention? In a randomized, double-blind, placebo-controlled experiment 18 healthy male volunteers received placebo/placebo, placebo/ketamine (0...
July 2009: International Journal of Neuropsychopharmacology
Todd D Watson, Ismene L Petrakis, Javon Edgecombe, Albert Perrino, John H Krystal, Daniel H Mathalon
In this double-blind, placebo-controlled study, we examined the effects of subanaesthetic doses of ketamine (an NMDA glutamate receptor antagonist) and thiopental (a GABA-A receptor agonist) on the event-related potential (ERP) correlates of deviant stimulus processing in 24 healthy adults. Participants completed three separate pharmacological challenge sessions (ketamine, thiopental, saline) in a counterbalanced order. EEG data were recorded both before and during each challenge while participants performed a visual 'oddball' task consisting of infrequent 'target' and 'novel' stimuli intermixed with frequent 'standard' stimuli...
April 2009: International Journal of Neuropsychopharmacology
B Oranje, B N van Berckel, C Kemner, J M van Ree, R S Kahn, M N Verbaten
A growing number of studies demonstrate that antagonists of the N-methyl-D-aspartate (NMDA) receptors can induce a broad range of psychophysiological anomalies in healthy subjects similar to those observed in schizophrenia. In this study, the effect of a sub-anaesthetic dose of the non-competitive NMDA antagonist, ketamine, on human selective attention was explored. It was hypothesized that ketamine would induce in healthy subjects psychophysiological anomalies that are commonly observed in schizophrenic patients, such as reduced P300 amplitude and a reduction of both mismatch negativity (MMN) and processing negativity (PN)...
March 2000: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"